COMPASS PATHWAYS PLC
CMPSNASDAQπ #2217 by market capEarnings Mar 22 Β· PostUS Equity
ββ
Quote unavailableTrack CMPS
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$1.14B
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
40
Weak
No chart data available for CMPS.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $4.88 β $15.87
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 141.7M
- Next Earnings
- 2027-03-22
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -1.9
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-1.92
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +36.8%
COMPASS PATHWAYS PLC
CMPSFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$179Mβ² +0.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$157Mβ² +31.9% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
93.6Mβ² +36.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$115MβΌ β$18M YoY
About COMPASS PATHWAYS PLC
COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
β‘Momentumβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Weak
40/100
Analyst data unavailable.
Latest News & Updates
News unavailable.